anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ABSTRACT OF THE DISCLOSURE    An aqueous emulsion of minute particles of calcium hydroxide formed by bringing porous and minute particles of practically pure calcium oxide into reaction with an excess amount of water is brought into reaction with an aqueous solution of phosphoric acid in an inert atmosphere, a milky reaction mixture containing the reaction product, hydroxyapatite is obtained.  After filtering, the separated cake is washed with water and dried to be an aggre-gate of hydroxyapatite having the following properties:          Analytical value of an atomic ratio of Ca/P: 1.67 to 1.69, Mean size of dimention of hydroxyapatite of length:  150 to 1200  .ANG. width:  50 to 400 A, and ratio of length/width:  3 to 10.  Void: 0.2 to 0.8 cm3/g Mean pore-radius: 50 to 150 .ANG..  By firing the filtered cake, a ceramic material of hydroxyapatite having the following physical properties is obtained:          Analytical value of Ca/P  : 1.67 to 1.69, Mean crystal size         : 4 to 20 microns, and Density                   : 3.14 to 3.16 g/cm3.          The mean crystal size of the thus obtained material is larger than that of conventional synthetic ceramic material of hydroxyapatite.          The ceramic material of the present invention is prepared from the purer raw materials than those used for preparing the con-ventional materials.  In addition, even after firing of  the aggregate of hydroxyapatite at a temperature of 1350°C for one hour, no formation of whitlockite occurs, and no structural defects or decomposition occurs and the aggregate is excellent in thermal stability.  This invention relates to hydroxyapatite, ceramic material, implant material and a process for preparing thereof.  The ceramic material is hydroxyapatite ceramic having an excellent thermal stability.
Kawasaki disease (KD), a systemic vasculitic condition predominantly affecting children, remains a significant challenge in pediatric health care. First identified in 1967, KD is now recognized as the primary cause of pediatric ischemic heart disease in developed countries. This review provides a comprehensive update of KD, focusing on biomarkers, pathophysiology, and genetic associations. KD's clinical manifestation, including symptoms such as persistent fever and mucocutaneous changes, often overlaps with other pediatric conditions, complicating its diagnosis. This ambiguity, especially in cases of incomplete KD, highlights the critical need for specific biomarkers and more precise diagnostic methods. Recent studies have made promising advancements in identifying serum biomarkers and microRNAs, contributing to the development of rapid diagnostic tools. However, these are yet to be fully integrated into clinical practice. The article focuses on the pathophysiological aspects of KD, highlighting the potential for targeted therapies and personalized medicine approaches based on genetic predispositions. Collaborative efforts in global research and raising public awareness about KD are emphasized as key strategies for improving its management. This review presents the current understanding of KD while pointing out the gaps and future directions in research and clinical care. The ultimate goal is to enhance diagnostic accuracy, optimize treatment strategies, and improve patient outcomes, thereby addressing the complexities of this enigmatic and potentially life-threatening condition in pediatric medicine.
Maintenance of intestinal barrier function contributes to gastrointestinal homeostasis and therefore cardiovascular diseases. A number of studies show that intestinal permeability is affected by excessive inflammatory responses. Krüppel-like factor (KLF) 4 is one of the critical transcriptional factors, which controls multiple immune responses. In this study we investigated the role of KLF4 in regulating intestinal inflammation and permeability during the atherosclerotic process. Atherosclerotic model was established in ApoE-/- mice by feeding a high fat high cholesterol (HFHC) diet. We showed that colon expression levels of KLF4 and tight junction proteins were significantly decreased whereas inflammatory responses increased in atherosclerotic mice. Overexpression of colon epithelial Klf4 decreased atherosclerotic plaque formation and vascular inflammation in atherosclerotic mice, accompanied by remarkable suppression of intestinal NF-κB activation. We found that overexpression of epithelial Klf4 in atherosclerotic mice significantly increased intestinal tight junction expression and ameliorated endotoxemia, whereas replenishment of LPS abolished these benefits. Overexpression of Klf4 reversed LPS-induced permeability and downregulation of ZO-1 and Occludin in Caco-2 cells in vitro. HFHC diet stimulated the expression of epithelial microRNA-34a, whereas silence of epithelial Klf4 abolished the benefits of microRNA-34a sponge, a specific miR-34a inhibitor, on intestinal permeability and atherosclerotic development. A clinical cohort of 24 atherosclerotic patients supported colon KLF4/NF-κB/tight junction protein axis mediated intestine/cardiovascular interaction in patients with atherosclerosis. Taken together, intestinal epithelial KLF4 protects against intestinal inflammation and barrier dysfunction, ameliorating atherosclerotic plaque formation.
The study will assess the potential for longer-latency cardiometabolic and pulmonary effects of early life exposure to the World Trade Center (WTC) disaster, and to identify opportunities for early identification of WTC-related health consequences. Preliminary data from the only investigators who regularly provide clinical care to children who lived/attended school near the WTC site identified decrements in spirometry associated with dust cloud exposure, and a remarkably high frequency of cardiometabolic risk factors. Findings from this clinically, self-selected population cannot be extrapolated to the entire population of children who were exposed to the disaster but nonetheless suggest that further study is warranted of the possible metabolic and cardiovascular consequences of WTC exposures. If associated with WTC exposures in a larger, more representative sample, two new and innovative techniques, oscillometry and pulse wave velocity assessment, hold great promise for earlier detection of WTC-related pulmonary and cardiometabolic disease, for whom dietary, environmental and medication interventions may prevent disease progression in later life.

The study will recruit 225 adolescents who respond to the WTC Health Registry (WTCHR), the most representative pediatric population and best-characterized from an environmental exposure standpoint. Connecting the study to the WTCHR also presents efficiency of federal resource utilization, providing more objective clinical data to support self-reported findings of increased persistent respiratory symptoms captured by the WTCHR, thereby improving reliability of the registry data. We will compare pulmonary and cardiometabolic outcomes to carefully matched (age, race/ethnicity, gender, and socioeconomic status) and unexposed control (not resident/attending school south of Houston Street on September 11, 2001) populations from NYU School of Medicine affiliated primary care (private and public clinics).
The present invention relates to a silica cream ketoconazole ointment and a preparation method thereof. The present invention is composed of dimethyl silica oil, liquid paraffin, stearic acid, glycerol, alcohol, ketoconazole, neomycin sulfate, dexamethasone, a proper number of emulsifying agent, and a proper amount of water. Firstly, the dimethyl silica oil, the liquid paraffin, the stearic acid, the glycerol, the alcohol, the emulsifying agent and the water respectively have a water bath to 90 DEG C according to an oil phase and a water phase; the oil phase is added in the water phase and is stirred; medicinal silica cream is prepared; then, the ketoconazole, the neomycin sulfate and the dexamethasone are added and uniformly mixed for obtaining the silica cream ketoconazole ointment. After the present invention is used, a user feels comfortable and does not have a greasy feeling. The present invention increases an antibacterial spectrum and an antibacterial function and does not have a side effect. After the present invention is used, a rebound phenomenon can not occur.
A 22-gauge needle is inserted at a puncture site lateral to the target spinous process using ultrasound imaging and advanced until contact is made with the transverse process. The local anesthetic agent will be injected between the transverse process and the erector spinae muscle using 20 ml (19ml bupivacaine 0.25% plus 1ml dexamethasone 4mg).
The safety, pharmacokinetics, and efficacy of HARVONI for treatment of HCV genotype 1 and 4 infection in treatment-naïve and treatment-experienced pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis have been established in an open-label, multicenter clinical trial (Study 1116, N=226; 186 treatment-naïve, 40 treatment-experienced) and are comparable to that observed in adults.

The safety and efficacy of HARVONI for treatment of HCV genotypes 5 or 6 infection in pediatric patients 3 years of age and older are supported by comparable ledipasvir, sofosbuvir, and GS-331007 exposures between adults and pediatric patients [see Dosage and Administration (2.2 and 2.4), Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.3, 14.6, 14.7)]. Similar rationale is used to support dosing recommendations for pediatric patients with HCV genotype 1 infection who have decompensated cirrhosis (Child-Pugh B or C) and for pediatric patients with HCV genotype 1 and 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis.

In patients with severe renal impairment, including those requiring dialysis, exposures of GS-331007, the inactive metabolite of sofosbuvir, are increased [see Clinical Pharmacology (12.3)]. No data are available regarding the safety of HARVONI in pediatric patients with renal impairment [see Use in Specific Populations (8.6)].

The safety and efficacy of HARVONI have not been established in pediatric patients less than 3 years of age.
Intervention group will take 12 sessions of acupuncture addition to their prophylaxis treatment. Acupuncture points will be bilateral LI-4, LI-11, ST-8, ST-44, SP-6, GB-1, GB-14, GB-20, LR-3, and GV-14, GV-20. Sterile and single-use stainless steel acupuncture needles measuring 0.25x25 mm will be inserted to a depth of 10 mm and be retained for 30 minute without any further stimulation. Acupuncture will be performed by an acupuncturist with an acupuncture practitioner licence from the Turkish Ministry of Health. Adverse events will be monitored for all acupuncture sessions.
The invention relates to a discovery of single prescription of apple-of-peru (entire plant: root, seed and flower) in treating cardiovascular disease, particularly in the preparation of cardiovascular disease medicine. The apple-of-peru is only used in edible gel and outdated pharmaceutical range in the past. For example, the apple-of-peru has heat and toxic material clearing away effect (used for treating edema and furuncle); and can be used for treating rabies, psychosis, epilepsy, rheumatalgia, sore and furuncle, common cold, etc. A new discovery is made in 2004 that the apple-of-peru has good curative effect on chronic nephropathy. Our clinical observation indicates that the apple-of-peru can be used for obviously treating patients of nephropathy accompanied with cardiovascular disease. Thus, one to twenty patients having cardiovascular disease without nephropathy are observed. It is summarized that the apple-of-peru (single prescription) medicinal decoction has good curative effect on cardiovascular disease, especially hypertension and coronary heart disease.
A medical infusion pump for delivering a medicament to a patient. The pump includes a user interface to display a choice of nominal medicament delivery rates. The user interface enables a practitioner to select one of the displayed nominal medicament delivery rates. It further enables the practitioner to enter a numerical multiplier factor, thereby creating a nominal delivery rate. It further enables the practitioner to create a custom alphanumeric string that the practitioner associates with a patient characteristic, enter a numeric value relating to the patient characteristic, and determine an actual delivery rate by modifying the selected nominal medicament delivery rate based on the numeric value relating to the patient characteristic. The pump mechanism is then controlled to deliver medicament from a reservoir to a patient at the actual delivery rate.
Metal implants are routinely placed in children for treatment of fracture or deformity. Long-term effects of indwelling metal implants are not well-understood. Data from this study will provide guidances as to whether some metals are safer for children (stainless vs. titanium alloys). In addition, we will document the presence of serum ion concentration for children with metal implants in place and whether this resolves after implant removal. Tissues adjacent to implants will be evaluated for signs of metallosis and wear debris. Presence of metallosis will be correlated with serum ion concentration. In vivo studies will provide data on whether metal exposure to bone cells and fibroblasts affects their inflammatory cascade and function. Based on these findings, surgeons can better counsel patients whether routine implant removal is advisable or whether stainless steel implants are safer for long-term retention compared to titanium implants. Further, novel drug targets for treatment and prevention of metallosis will be developed. This project will foster collaboration and future partnerships between the Sanford Health and Mayo Clinic research teams
For the experiment group, the clinician will be providing participant with daily 0.4 gram mBerry tablets (total of 112 tablets) to consume twice a day (for two meals) over an 8-week period. The participant will be provided with a log form to track mBerry use for the two meals each day for the 8-week period. They will be requested to bring log to each of the clinical visits which include bi-weekly taste assessments.
Children under two are consuming less than half of their daily energy requirements (560 kcal) and lower than recommended levels of micronutrients (one-third of reference nutrient intake for Iron and one-half for Zinc). Overall, less than 4% of children were receiving an acceptable, diverse diet. Food security and nutrition situation in Sindh province is even more dramatic. According to the National Nutrition Survey, 2011, GAM prevalence exceeds 18% while anemia levels amongst children under five reached the alarming level of 72.5%. With this high level of poverty and food insecurity, a food based approach to prevent stunting, together with non- food based approaches is needed.

Therefore, Division of Women and Child Health, Aga Khan University proposes a research study for stronger evidence base on the effectiveness of preventive food/nutrient based interventions on reduction of stunting and developing viable programmes on nutrition under "real" operational conditions. The effectiveness of the project will be measured in terms of the impact of the proposed interventions on the stunting and micronutrient deficiency prevalences in the target group (children and mothers). Given the conditions of project implementation, a quasi-experimental "double difference" design would be appropriate to assess the impact of the intervention. We propose to compare the intervention and non-intervention (control) groups before (first difference) and after the intervention (second difference). Then, the operational implementation of the research comprises a baseline and end line surveys. In addition, a nested cluster randomized controlled trial will be implemented to track the evolution of key variables related to the quality of intervention delivery and intermediate nutrition outcomes. The control clusters will receive routine public and private health services available in the area.

To achieve its purpose and objectives the project design includes core interventions such as complementary feeding using food/nutrient based supplements along with behavior change communication, complemented with other non-food interventions. Using a preventative (blanket) approach, three types of food/nutrient supplements (Wawamum, MNP \& WSB) are considered as part of the interventions.
The invention discloses a method for preparing a population of human pluripotent stem cells and the application thereof. The preparation of stem cells is characterized by comprising the following steps: CD151<+>, CD31<->, Sox<2+> pluripotent stem cells are separated and collected from human umbilical cord and or placenta tissues; the cells adhere to grow in a culture vessel under a predetermined condition and expand through passage 20 or above to be still stable in gene expression. The population of cells of this invention do not form teratoma after injection into animals. The human pluripotent stem cells highly express CD151, OCT4 and Sox-2 as specific markers of embryonic stem cells, as well as specific markers of epidermic cells, endothelial cells, thrombocytes, dendritic cells, while lack expression of CD31, CD34, CD45 and HLA-II. The pluripotent stem cells are also characterized as being able to adhere to tissue culture plastic and having the potential to differentiate into three germ layers: endoderm, mesoderm and ectoderm. These pluripotent stem cells are able to be used as carrier cells of gene therapy and for the treatment of diseases caused by cell damage or cell aging. The present invention provides a method of isolating, purifying and culturally expanding of a population of human pluripotent stem cell for preparing the high purity injection preparation. The preparation of stem cells has a good therapeutic effect on the treatment of diseases caused by cell damage or cell aging in animal and human clinical trials. The preparation also has no toxic side effect and no immune rejection.
Participants will be given their results of their antibody test after 4 weeks. Their engagement with SARS-CoV-2 prevention behaviors will also be assessed following testing.
The patients with temporal lobe epilepsy (TLE) admitted in the Department of Neurology, Zhongshan Hospital, Fudan University from June 2009 to February 2012 were prospectively enrolled. The diffusion tensor imaing was performed on the patients at the time of enrollment and 3 years later. The fractional anisotropy (FA) values of the white matter connecting fibers(bilateral hooked, arcuate, cingulate, and superior longitudinal tracts), the connecting fibers of both hemispheres(anterior union, anterior callosal forceps, posterior forceps, and bilateral fornix), and fibers of perirhinal cortices system(bilateral radiating crown and anterior limb of the internal capsule) were measured by the region of interest method. The severity of epilepsy was evaluated using the Veterans Administration Seizure Type and Frequency Rating Scale(VA-2) and National Hospital Seizure Severity Scale (NHS3). A total of 51 patients with TLE were screened, with 27 patients completing the 3-year follow-up. There were 13 males and 14 females with an age of (32±11) years and a follow-up duration of (39.1±1.1) months. During the follow-up, 6 patients had increased/unchanged NHS3 or VA-2 scores, while 21 patients had decreased scores. Three years later, the FA values of the bilateral arcuate fasciculus, the right superior longitudinal fasciculus, the right radial coronal and corpus callosum anterior forceps in TLE patients decreased compared to baseline(P<0.05). However, compared to the patients with decreased VA-2 scores during the follow-up, the degree of increase in FA values (ΔFA, follow-up FA value-baseline FA value) of the ipsilateral hook bundle caused by epilepsy was more significant in the group with increased/unchanged VA-2 scores (decreased score group vs increased/unchanged score group:-0.032±0.063 vs 0.018±0.043, t=2.305, P=0.035). The value of ΔFA in epileptic patients with increased/unchanged NHS3 scores (0.075±0.113) was higher compared to those with decreased scores (-0.079±0.099, t=2.804, P=0.010). Correlation analysis also showed the changes in FA values of epileptic lateral fasciculus (r=0.503, P=0.009) and arcuate fasciculus (r=0.602, P=0.001)were positively correlated with the changes in VA-2 and HNS3 scores, respectively. The seizure severity in patients with TLE was closely associated with the microstructure changes in the frontal and temporal white matter, especially the arcuate and uncinate tracts, on the same side that caused seizures, which may indicate the white matter remodeling and abnormal network reformation associated with seizures.
PURPOSE: A pharmaceutical composition containing Clematis chinensis extract for preventing and treating ischemic brain diseases is provided to suppress neural cell apoptosis. CONSTITUTION: A pharmaceutical composition for preventing and treating ischemic brain disease contains Clematis chinensis extract as an active ingredient. The prevention and treatment for ischemic brain disease is caused from neural cell protection. The ischemic brain disease is ischemic stroke. The Clematis chinensis extract is obtained by isolating the root of Clematis chinensis using 70% of ethanol solution. The Clematis chinensis extract is contained in 0.1-50 weight% based on total weight of the composition. The composition is used in the form of powder, tablet, capsule, injection or liquid.
PURPOSE:The titled pharmaceutical prepared by fixing an antiulcer substance and a blood coagulating agent in a structure of an in vivo nonabsorbing substance as a material, and useful for treating and diagnosing cancers or tumors. CONSTITUTION:A prolonged releasing embolic agent of an antiulcer substance prepared by fixing the antiulcer substance, e.g. an alkylating agent, metabolic antagonistic agent or antibiotic substance, and a blood coagulating agent, e.g. blood coagulation factor VIII or thrombin, in a structure of an in vivo nonabsorbing substance, e.g. a silicone, as materials in the form of a fiber aggregate, e.g. sponge, powder, monofilaments, films or microcapsules. In case the agent is used in the therapy which is a therapy for cancer, the embolus of blood vessels can be rapidly and surely carried out. The agent is capable of effectively reacting the antiulcer substance with the cancer or tumorous tissues for a long time. In case the agent is used for the needle piercing method, the bleeding in the operation can be rapidly and surely suppressed to restore the damaged blood vessel in an early stage. The substances are fixed in the above-mentioned structure by linking, adsorbing or entrapping method, etc.